Adalvo and Hikma Sign Exclusive Licensing Agreement to Commercialise a product in the Allergic Rhinitis space across MENA Markets
Adalvo has announced that Adalvo has signed an exclusive licensing agreement with Hikma Pharmaceuticals PLC (Hikma), a multinational pharmaceutical company, to commercialise a nasal spray indicated in the treatment of Allergic Rhinitis (AR) one of the main respiratory diseases with increasing prevalence.
The new exclusive licensing and supply deal with Hikma expands Adalvo’s respiratory endeavours in MENA. The licensed product is a combination treatment in a single advanced delivery system that has proven efficacy and safety in treating patients with AR. This medication will help more patients control their respiratory disease symptoms, with an advantage of a faster onset of action and fewer adverse effects.
Anil Okay, CEO at Adalvo
We are thrilled to be partnering with Hikma, a well-established multinational Company having a track record of creating high-quality medicines and making them accessible to the people who need them. This collaboration further accelerates our growth at an international level, and underlines our capabilities of bringing differentiated, high value products to the market, whilst also expanding our allergy and respiratory pipeline.
Mazen Darwazah, Hikma’s Executive Vice Chairman and President of MENA.
This latest agreement with Adalvo aligns with our strategy of creating a well-diversified pipeline of high-value products, while further solidifying our commercial presence in MENA. By partnering with a dynamic and progressive company like Adalvo, we are building on our ongoing commitment to offering patients access to high-quality respiratory medications that actively support their treatment journey towards better health.